EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 34 / Numéro 3 (Mars 2018) Med Sci (Paris), 34 3 (2018) 231-237 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 34, Numéro 3, Mars 2018
Page(s) 231 - 237
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20183403011
Publié en ligne 16 mars 2018
  1. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987; 165 : 302-19. [CrossRef] [PubMed] [Google Scholar]
  2. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355 : 1018-28. [Google Scholar]
  3. Badoual C, Combe P, Gey A, et al. Signification et intérêt clinique de l’expression de PD-1 et PDL-1 dans les tumeurs. Med Sci (Paris) 2013; 29 : 570-2. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  4. Bettini M, Szymczak-Workman AL, Forbes K, et al. Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3. J Immunol 2011; 187 : 3493-8. [CrossRef] [PubMed] [Google Scholar]
  5. Joller N, Hafler JP, Brynedal B, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol 2011; 186 : 1338-42. [CrossRef] [PubMed] [Google Scholar]
  6. Wherry EJ. T cell exhaustion. Nat immunol 2011; 12 : 492-9. [CrossRef] [PubMed] [Google Scholar]
  7. Apetoh L, Smyth MJ, Drake CG, et al. Consensus nomenclature for CD8+ T cell phenotypes in cancer. Oncoimmunology 2015; 4 : e998538. [CrossRef] [PubMed] [Google Scholar]
  8. Kim HJ, Barnitz RA, Kreslavsky T, et al. Stable inhibitory activity of regulatory T cells requires the transcription factor Helios. Science 2015; 350 : 334-9. [Google Scholar]
  9. Singer M, Wang C, Cong L, et al. A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T Cells. Cell 2016; 166 : 1500-11 e9. [Google Scholar]
  10. Tirosh I, Izar B, Prakadan SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 2016; 352 : 189-96. [Google Scholar]
  11. Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002; 415 : 536-41. [CrossRef] [PubMed] [Google Scholar]
  12. Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat immunol 2005; 6 : 1245-52. [CrossRef] [PubMed] [Google Scholar]
  13. Oomizu S, Arikawa T, Niki T, et al. Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner. Clin immunol 2012; 143 : 51-8. [CrossRef] [PubMed] [Google Scholar]
  14. Granier C, Dariane C, Combe P, et al. Tim-3 Expression on tumor-infiltrating PD-1+CD8+ T cells correlates with poor clinical outcome in renal cell carcinoma. Cancer Res 2017; 77 : 1075-82. [Google Scholar]
  15. Nakayama M, Akiba H, Takeda K, et al. Tim-3 mediates phagocytosis of apoptotic cells and crosspresentation. Blood 2009; 113 : 3821-30. [Google Scholar]
  16. Huang YH, Zhu C, Kondo Y, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 2015; 517 : 386-90. [CrossRef] [PubMed] [Google Scholar]
  17. Rangachari M, Zhu C, Sakuishi K, et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat Med 2012; 18 : 1394-400. [CrossRef] [PubMed] [Google Scholar]
  18. Huang RY, Eppolito C, Lele S, et al. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget 2015; 6 : 27359-77. [CrossRef] [PubMed] [Google Scholar]
  19. Zhu C, Sakuishi K, Xiao S, et al. An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nat commun 2015; 6 : 6072. [CrossRef] [PubMed] [Google Scholar]
  20. Dannenmann SR, Thielicke J, Stockli M, et al. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology 2013; 2 : e23562. [CrossRef] [PubMed] [Google Scholar]
  21. Chiba S, Baghdadi M, Akiba H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat immunol 2012; 13 : 832-42. [Google Scholar]
  22. Sakuishi K, Ngiow SF, Sullivan JM, et al. TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology 2013; 2 : e23849. [CrossRef] [PubMed] [Google Scholar]
  23. Moorman JP, Wang JM, Zhang Y, et al. Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection. J Immunol 2012; 189 : 755-66. [CrossRef] [PubMed] [Google Scholar]
  24. Kurtulus S, Sakuishi K, Ngiow SF, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest 2015; 125 : 4053-62. [CrossRef] [PubMed] [Google Scholar]
  25. Gleason MK, Lenvik TR, McCullar V, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 2012; 119 : 3064-72. [Google Scholar]
  26. Ndhlovu LC, Lopez-Verges S, Barbour JD, et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 2012; 119 : 3734-43. [Google Scholar]
  27. da Silva IP, Gallois A, Jimenez-Baranda S, et al. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res 2014; 2 : 410-22. [CrossRef] [PubMed] [Google Scholar]
  28. Xu L, Huang Y, Tan L, et al. Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int immunopharmacol 2015; 29 : 635-41. [Google Scholar]
  29. Yang X, Jiang X, Chen G, et al. T cell Ig mucin-3 promotes homeostasis of sepsis by negatively regulating the TLR response. J Immunol 2013; 190 : 2068-79. [CrossRef] [PubMed] [Google Scholar]
  30. Giraldo NA, Becht E, Pages F, et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res 2015; 21 : 3031-40. [CrossRef] [PubMed] [Google Scholar]
  31. Badoual C, Hans S, Merillon N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73 : 128-38. [Google Scholar]
  32. Thommen DS, Schreiner J, Muller P, et al. Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol Res 2015; 3 : 1344-55. [CrossRef] [PubMed] [Google Scholar]
  33. Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207 : 2175-86. [CrossRef] [PubMed] [Google Scholar]
  34. Gros A, Robbins PF, Yao X, et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014; 124 : 2246-59. [CrossRef] [PubMed] [Google Scholar]
  35. Djenidi F, Adam J, Goubar A, et al. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol 2015; 194 : 3475-86. [CrossRef] [PubMed] [Google Scholar]
  36. Nizard M, Roussel H, Diniz MO, et al. Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat commun 2017; 8 : 15221. [CrossRef] [PubMed] [Google Scholar]
  37. Sandoval F, Terme M, Nizard M, et al. Mucosal imprinting of vaccine-induced CD8+ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 2013; 5 : 172ra20. [Google Scholar]
  38. Li H, Wu K, Tao K, et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virusassociated hepatocellular carcinoma. Hepatology 2012; 56 : 1342-51. [CrossRef] [PubMed] [Google Scholar]
  39. Ngiow SF, von Scheidt B, Akiba H, et al. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011; 71 : 3540-51. [Google Scholar]
  40. Chauvin JM, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest 2015; 125 : 2046-58. [CrossRef] [PubMed] [Google Scholar]
  41. Giraldo NA, Becht E, Vano Y, et al. Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin Cancer Res 2017; 23 : 4416-28. [CrossRef] [PubMed] [Google Scholar]
  42. Yang ZZ, Grote DM, Ziesmer SC, et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 2012; 122 : 1271-82. [CrossRef] [PubMed] [Google Scholar]
  43. Gao X, Yang J, He Y, Zhang J. Quantitative assessment of TIM-3 polymorphisms and cancer risk in Chinese Han population. Oncotarget 2016; 7 : 35768-75. [PubMed] [Google Scholar]
  44. Paley MA, Kroy DC, Odorizzi PM, et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 2012; 338 : 1220-5. [Google Scholar]
  45. Kamphorst AO, Wieland A, Nasti T, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 2017; 355 : 1423-7. [Google Scholar]
  46. Koyama S, Akbay EA, Li YY, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 2016; 7 : 10501. [CrossRef] [PubMed] [Google Scholar]
  47. Shayan G, Srivastava R, Li J, et al. Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. Oncoimmunology 2016; 6 : e1261779. [Google Scholar]
  48. Odorizzi PM, Pauken KE, Paley MA, et al. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J Exp Med 2015; 212 : 1125-37. [CrossRef] [PubMed] [Google Scholar]
  49. Zhou Q, Munger ME, Veenstra RG, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011; 117 : 4501-10. [Google Scholar]
  50. Pignon J-C, Jegede O, Mahoney KM, et al. Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8+ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC). J Clin Oncol 2017; 35 : 477. [Google Scholar]
  51. Torras OR, Marin-Aguilera M, Jiménez N, et al. Molecular profile of sunitinib resistance in clear-cell renal cell carcinoma. Cancer Res 2017; 77 (suppl 13) : abstract 785. [Google Scholar]
  52. Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207 : 2187-94. [CrossRef] [PubMed] [Google Scholar]
  53. Kim JE, Patel MA, Mangraviti A, et al. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res 2016; 23 : 124-36. [CrossRef] [PubMed] [Google Scholar]
  54. Takamura S, Tsuji-Kawahara S, Yagita H, et al. Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors. J Immunol 2010; 184 : 4696-707. [CrossRef] [PubMed] [Google Scholar]
  55. Gefen T, Castro I, Muharemagic D, et al. A TIM-3 oligonucleotide aptamer enhances T cell functions and potentiates tumor immunity in mice. Mol Ther 2017; 25 : 2280-8. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.